Skip to Main Content
Phase COVID-II

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

  • Study HIC#:2000028181
  • Last Updated:09/08/2020

This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

  • Age18 years and older
  • GenderBoth
  • Start Date08/30/2020
  • End Date01/30/2023

Trial Purpose and Description

This is a randomized, blinded Phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

Eligible subjects will be randomized in a 1:1 ratio to receive either convalescent plasma (CP) from people who have recovered from COVID-19 containing antibodies to SARS-CoV-2 or a placebo control, Lactated Ringer's Solution (LR) or saline solution (SS). Hospitalized COVID-19 patients aged ?18 years of age with respiratory symptoms within 3 to 7 days from the onset of illness OR within 3 days of hospitalization will be eligible to participate.

Eligibility Criteria

Inclusion Criteria

  1. Patients ≥18 years of age
  2. Hospitalized with laboratory confirmed COVID-19
  3. One or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal CXR/CT imaging)
  4. Hospitalized for ≤ 72 hours OR within day 3 to 7 days from first signs of illness
  5. On supplemental oxygen, non-invasive ventilation or high-flow oxygen
  6. Patients may be on other randomized controlled trials of pharmaceuticals for COVID -19 and patients who meet eligibility criteria will not be excluded on this basis.

Exclusion Criteria

  1. Receipt of pooled immunoglobulin in past 30 days
  2. Contraindication to transfusion or history of prior reactions to transfusion blood products
  3. Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  4. Volume overload secondary to congestive heart failure or renal failure
  5. Unlikely to survive past 72 hours from screening based on the assessment of the investigator
  6. Unlikely to be able to assess and follow outcome due to poor functional status